Recombia Biosciences is a metabolic engineering platform that leverages the infinite potential of microorganisms for producing commercial scale ingredients. Our powerful partnership with Lesaffre enables cutting-edge solutions for industrial biomanufacturing to better nourish and protect the planet.
In 2020, upon the rapid achievement of several technical milestones, Recombia Biosciences was acquired by Lesaffre Group. As a subsidiary of Lesaffre Group, Recombia’s cutting edge metabolic engineering capabilities are an essential pillar to Lesaffre’s global R&D ecosystem.
In 2021, Recombia opened their first labs in San Francisco.
In 2022, Recombia expanded their footprint to Greater Boston through the acquisition of an innovative natural product discovery pipeline from Double Rainbow Bio.
After the successful launch of their first product in 2023, Recombia Biosciences formally transferred their HQ to Boston positioning themselves at the epicenter of biotech innovation.
As of September 2024, Recombia Biosciences has 150 employees and a robust discovery pipeline that serves metabolic engineering solutions to both internal and external partners in the biomanufacturing ecosystem.